Suraksha Diagnostic Limited has informed the Exchange regarding Grant of 19802 Options.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suraksha Diagnostic has granted 19,802 stock options to eligible employees under its ESOP 2024 scheme, called 'ESOP Grant II'. The Nomination and Remuneration Committee approved this on 8 August 2025, and the grant is within the overall shareholder-approved limit of 5,00,000 equity shares. Each option is convertible into one equity share of ₹2 face value at an exercise price of ₹228 per share, a price that was predetermined in a Letter of Intent dated 15 November 2024. Options will vest over four years (15% in year 1, 25% in year 2, 30% in year 3, and 30% in year 4), subject to continued employment and certain performance criteria. Eligible grantees are employees who have moved from probation to confirmed status. The company received in-principle approvals for the scheme from NSE and BSE on 24 July 2025.
This is a routine ESOP grant well within shareholder-approved limits and represents only about 4% of the total ESOP pool being used so far. Existing shareholders may see minor future dilution if and when these options are exercised, but the impact on stock price is expected to be negligible in the near term.